However, cancers harbouring EML4‐ALK V3 tend to respond less well to ALK inhibitors compared with cancers driven by EML4‐ALK V1 (Kwak et al, 2010; Shaw et al, 2011; Solomon et al, 2014; Woo et al, 2017; Christopoulos et al, 2018). The gene discussed is EML4; the disease is cancer.